drugset / Trial / NCT02903121

Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users

NCT02903121

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The etonogestrel (ENG) subdermal contraceptive implant (ENG implant) is a highly effective method of preventing pregnancy, but it has bleeding side effects that make it unappealing for many women. The only study to demonstrate a sustained reduction in bleeding lasting for two months was the selective estrogen receptor modulator (SERM) tamoxifen in users of the levonogestrel (LNG) contraceptive implant. Based on the investigators encouraging preliminary data of tamoxifen and ENG implant users, the investigators plan to perform additional studies on the impact of tamoxifen on the breakthrough bleeding experience by ENG implant users.

Timeline

Start
2017-01-20
Primary completion
2019-06-05
Completion
2019-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamoxifen Small molecule 10 mg Oral

Indications